Eli Lilly's oral pill for weight loss and diabetes demonstrated success in another late-stage clinical trial. getty

The pharmaceutical giant Eli Lilly announced last week that its investigational drug, orforglipron, proved effective in a third late-stage clinical trial. The once-daily pill helps patients with obesity and type 2 diabetes lose weight and lower their blood sugar levels. Still, challenges remain, which include relatively high discontinuation rates that appear to be the result of adverse side effects, as well as questions pertaining to pricing and insurance coverage once the product is approved by the Food and Drug Administration.

The highest dose of orforglipron helped patients lose on average 10.5% of their weight, or 22.9 pounds, on average at 72 weeks, compared to 2.2

See Full Page